Overview

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

Status:
Active, not recruiting

Trial end date:
2023-04-30

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to find out if the drugs MEK162 and erlotinib (Tarceva) given in combination are safe and have beneficial effects in patients who have NSCLC. The U.S. Food and Drug Administration (FDA) has not approved MEK162 for use to treat NSCLC. Erlotinib is an FDA approved drug for the treatment of Non-Small Cell Lung Cancer.

Phase:

Phase 1

Details

Lead Sponsor:

H. Lee Moffitt Cancer Center and Research Institute

Collaborator:

Array BioPharma

Treatments:

Erlotinib Hydrochloride
Mitogens